Latest Headlines

  1. Insilico Medicine Receives FDA Fast Track Designation For ISM6331, The AI-driven Pan-TEAD Inhibitor, In Advanced Mesothelioma 7/28/2026

    Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that ISM6331, a novel, potential best-in-class pan-TEAD inhibitor driven by Insilico’s proprietary AI, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA), for the treatment of adult patients with unresectable malignant pleural mesothelioma whose disease has progressed on or after prior treatment with anti-PD-1 antibody therapy, with or without anti-CTLA-4 antibody therapy, and platinum-based chemotherapy.

  2. Dasher Neuroscience Completes Patient Enrollment In Phase 2 Global Clinical Trial Of Lead AI Drug Candidate YA-101 For Multiple System Atrophy (MSA) 7/28/2026

    Dasher Neuroscience Holdings Inc. (TPEx: 7829) ("Dasher Neuroscience"), an AI-driven biopharmaceutical company focused on central nervous system (CNS) drug discovery and development, today announced that it has successfully completed patient enrollment in its global, multi-center Phase 2 clinical trial evaluating YA-101, its flagship candidate for the treatment of Multiple System Atrophy (MSA).

  3. CORE Biomedicine Signs Exclusive Licensing Agreement With Eisai For Precision Oncology Programs 7/28/2026

    CORE Biomedicine, an innovative drug discovery company developing next-generation precision medicines for broader populations of cancer patients, announced a licensing agreement with Eisai Co., Ltd., granting CORE exclusive global rights to develop and commercialize multiple preclinical oncology programs.

  4. AbelZeta Receives FDA Clearance Of Registrational Phase II Trial For C-CAR168 In Refractory Lupus Nephritis 7/27/2026

    AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced that the Company received the U.S. Food and Drug Administration (FDA) clearance under its Regenerative Medicine Advanced Therapy (RMAT) designation regarding the multiple-center registrational Phase II clinical trial for C-CAR168, an anti-CD20/BCMA bispecific CAR-T, in the treatment of patients with Lupus Nephritis (LN) refractory to standard therapy.

  5. Bio-Thera Solutions Announces First Patient Dosed In Phase 1 Study For BAT8013, An Antibody Drug Conjugate Targeting CD25 For The Treatment Of Advanced Solid Tumors 7/23/2026

    Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8013, an antibody drug conjugate (ADC) that targets CD25.

  6. MindWalk Showcases ReefIQ For AI Drug Discovery At AMD Advancing AI 7/23/2026

    MindWalk Holdings Corp. (“MindWalk”), a Bio-Native AI company, today unveiled the first public demonstration of ReefIQ, its biological context layer for AI drug discovery, running on AMD Instinct at AMD’s Advancing AI 2026 in San Francisco.

  7. Thyora Therapeutics Launches To Build A Next-Generation Platform For Covalent Drug Discovery 7/23/2026

    Thyora Therapeutics today emerged from stealth as a biotechnology company leveraging next-generation covalent chemistry, with a mission to accelerate clinical translation and create therapies for high-unmet medical needs.

  8. SITC Announces EU Immuno-Oncology Drug Development Summit - Bringing The European IO Community Together To Foster The Next Wave Of IO Therapeutics 7/22/2026

    The Society for Immunotherapy of Cancer (SITC) is proud to announce the upcoming EU Immuno-oncology Drug Development Summit, taking place in Lausanne, Switzerland on Sept. 3–4, 2026, at the Agora Cancer Research Center.

  9. GCCL And GemPharmatech Sign MOU To Advance Global Drug Discovery And Development Services 7/22/2026

    GCCL, a South Korea-based leading provider of clinical trial sample analysis, and GemPharmatech, a global provider of in vivo efficacy testing and genetically engineered animal models, announced the signing of a Memorandum of Understanding (MOU) to promote mutual collaboration in delivering integrated drug discovery and development services to pharmaceutical and biotechnology companies worldwide.

  10. Revolution Medicines' New Drug Application For Daraxonrasib Accepted For Review By U.S. FDA For Previously Treated Metastatic Pancreatic Cancer 7/22/2026

    Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company’s New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).